FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280510519> ?p ?o ?g. }

• W4280510519 endingPage "1200" @default.
• W4280510519 startingPage "1191" @default.
• W4280510519 abstract "The coronavirus disease 2019 (COVID-19) antiviral nirmatrelvir/ritonavir (Paxlovid) has been granted authorization or approval in several countries for the treatment of patients with mild to moderate COVID-19 at high risk of progression to severe disease and with no requirement for supplemental oxygen. Nirmatrelvir/ritonavir will be primarily administered outside the hospital setting as a 5-day course oral treatment. The ritonavir component boosts plasma concentrations of nirmatrelvir through the potent and rapid inhibition of the key drug-metabolizing enzyme cytochrome P450 (CYP) 3A4. Thus nirmatrelvir/ritonavir, even given as a short treatment course, has a high potential to cause harm from drug-drug interactions (DDIs) with other drugs metabolized through this pathway. Options for mitigating risk from DDIs with nirmatrelvir/ritonavir are limited due to the clinical illness, the short window for intervention, and the related difficulty of implementing clinical monitoring or dosage adjustment of the comedication. Pragmatic options are largely confined to preemptive or symptom-driven pausing of the comedication or managing any additional risk through counseling. This review summarizes the effects of ritonavir on drug disposition (i.e., metabolizing enzymes and transporters) and discusses factors determining the likelihood of having a clinically significant DDI. Furthermore, it provides a comprehensive list of comedications likely to be used in COVID-19 patients which are categorized according to their potential DDI risk with nirmatrelvir/ritonavir. It also discusses recommendations for the management of DDIs which balance the risk of harm from DDIs with a short course of ritonavir, against unnecessary denial of nirmatrelvir/ritonavir treatment." @default.
• W4280510519 created "2022-05-22" @default.
• W4280510519 creator A5001691349 @default.
• W4280510519 creator A5007876312 @default.
• W4280510519 creator A5017420608 @default.
• W4280510519 creator A5021568119 @default.
• W4280510519 creator A5041365930 @default.
• W4280510519 creator A5042249868 @default.
• W4280510519 creator A5047434629 @default.
• W4280510519 creator A5048050447 @default.
• W4280510519 creator A5056456103 @default.
• W4280510519 creator A5058715015 @default.
• W4280510519 creator A5082174251 @default.
• W4280510519 creator A5087367098 @default.
• W4280510519 date "2022-06-07" @default.
• W4280510519 modified "2023-10-11" @default.
• W4280510519 title "Recommendations for the Management of Drug–Drug Interactions Between the <scp>COVID</scp> ‐19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications" @default.
• W4280510519 cites W1500920871 @default.
• W4280510519 cites W1564607482 @default.
• W4280510519 cites W1964678251 @default.
• W4280510519 cites W1987511213 @default.
• W4280510519 cites W2004125947 @default.
• W4280510519 cites W2018464571 @default.
• W4280510519 cites W2043764373 @default.
• W4280510519 cites W2045288713 @default.
• W4280510519 cites W2068634821 @default.
• W4280510519 cites W2072565182 @default.
• W4280510519 cites W2092629624 @default.
• W4280510519 cites W2112894490 @default.
• W4280510519 cites W2117610565 @default.
• W4280510519 cites W2124502379 @default.
• W4280510519 cites W2125160586 @default.
• W4280510519 cites W2156318777 @default.
• W4280510519 cites W2163127317 @default.
• W4280510519 cites W2163974352 @default.
• W4280510519 cites W2294678755 @default.
• W4280510519 cites W2412168314 @default.
• W4280510519 cites W2464755384 @default.
• W4280510519 cites W2516907849 @default.
• W4280510519 cites W2601701713 @default.
• W4280510519 cites W2752033985 @default.
• W4280510519 cites W2787903782 @default.
• W4280510519 cites W2800330775 @default.
• W4280510519 cites W2810116592 @default.
• W4280510519 cites W2823433919 @default.
• W4280510519 cites W2908395843 @default.
• W4280510519 cites W2914208687 @default.
• W4280510519 cites W2919626818 @default.
• W4280510519 cites W2924629992 @default.
• W4280510519 cites W2938196622 @default.
• W4280510519 cites W2945424168 @default.
• W4280510519 cites W2969854436 @default.
• W4280510519 cites W3036190288 @default.
• W4280510519 cites W3047565267 @default.
• W4280510519 cites W3092968229 @default.
• W4280510519 cites W3123418636 @default.
• W4280510519 cites W4206767719 @default.
• W4280510519 cites W4210948121 @default.
• W4280510519 cites W4211234541 @default.
• W4280510519 cites W4213212413 @default.
• W4280510519 cites W4221017541 @default.
• W4280510519 cites W4226140942 @default.
• W4280510519 cites W4226236384 @default.
• W4280510519 doi "https://doi.org/10.1002/cpt.2646" @default.
• W4280510519 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35567754" @default.
• W4280510519 hasPublicationYear "2022" @default.
• W4280510519 type Work @default.
• W4280510519 citedByCount "82" @default.
• W4280510519 countsByYear W42805105192022 @default.
• W4280510519 countsByYear W42805105192023 @default.
• W4280510519 crossrefType "journal-article" @default.
• W4280510519 hasAuthorship W4280510519A5001691349 @default.
• W4280510519 hasAuthorship W4280510519A5007876312 @default.
• W4280510519 hasAuthorship W4280510519A5017420608 @default.
• W4280510519 hasAuthorship W4280510519A5021568119 @default.
• W4280510519 hasAuthorship W4280510519A5041365930 @default.
• W4280510519 hasAuthorship W4280510519A5042249868 @default.
• W4280510519 hasAuthorship W4280510519A5047434629 @default.
• W4280510519 hasAuthorship W4280510519A5048050447 @default.
• W4280510519 hasAuthorship W4280510519A5056456103 @default.
• W4280510519 hasAuthorship W4280510519A5058715015 @default.
• W4280510519 hasAuthorship W4280510519A5082174251 @default.
• W4280510519 hasAuthorship W4280510519A5087367098 @default.
• W4280510519 hasBestOaLocation W42805105192 @default.
• W4280510519 hasConcept C142462285 @default.
• W4280510519 hasConcept C159047783 @default.
• W4280510519 hasConcept C177713679 @default.
• W4280510519 hasConcept C2779298103 @default.
• W4280510519 hasConcept C2780035454 @default.
• W4280510519 hasConcept C2993143319 @default.
• W4280510519 hasConcept C3013748606 @default.
• W4280510519 hasConcept C71924100 @default.
• W4280510519 hasConcept C98274493 @default.
• W4280510519 hasConceptScore W4280510519C142462285 @default.
• W4280510519 hasConceptScore W4280510519C159047783 @default.
• W4280510519 hasConceptScore W4280510519C177713679 @default.
• W4280510519 hasConceptScore W4280510519C2779298103 @default.
• W4280510519 hasConceptScore W4280510519C2780035454 @default.

• next